MARKETS
Earnings

Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY

Sep 3, 2026 · 05:04 PM ET· updated 45m ago

Latigo Biotherapeutics (NASDAQ:LTGO) reported quarterly losses of $(27.59) per share. This is a 24.45 percent increase over losses of $(36.52) per share from the same period last year. The company reported $0.00 in

Share
Why It Matters

Latigo lost less money per share this quarter than last year, which is a small step forward. When a company that's still losing money starts losing less, it might mean their plan is starting to work—but they still have a long way to go.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.